BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 8383286)

  • 1. Synergistic induction of apoptosis with glucocorticoids and 3',5'-cyclic adenosine monophosphate reveals agonist activity by RU 486.
    Gruol DJ; Altschmied J
    Mol Endocrinol; 1993 Jan; 7(1):104-13. PubMed ID: 8383286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of human leukemic CEM-C1 cells is overcome by synergism between glucocorticoid and protein kinase A pathways: correlation with c-Myc suppression.
    Medh RD; Saeed MF; Johnson BH; Thompson EB
    Cancer Res; 1998 Aug; 58(16):3684-93. PubMed ID: 9721879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid and cyclic adenosine 3'5'-monophosphate-mediated induction of cholesterol side-chain cleavage cytochrome P450 (P450scc) in MA-10 tumor Leydig cells. Increases in mRNA are cycloheximide sensitive.
    Hales DB; Sha L; Payne AH
    Endocrinology; 1990 Jun; 126(6):2800-8. PubMed ID: 2161734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3',5'-cyclic adenosine monophosphate response element-binding protein and CCAAT enhancer-binding protein are dispensable for insulin inhibition of phosphoenolpyruvate carboxykinase transcription and for its synergistic induction by protein kinase A and glucocorticoids.
    Yeagley D; Quinn PG
    Mol Endocrinol; 2005 Apr; 19(4):913-24. PubMed ID: 15604115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic induction of tissue-type plasminogen activator gene expression by glucocorticoids and cyclic nucleotides in rat HTC hepatoma cells.
    Kathju S; Heaton JH; Bruzdzinski CJ; Gelehrter TD
    Endocrinology; 1994 Sep; 135(3):1195-204. PubMed ID: 8070363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of 3',5'-cyclic adenosine monophosphate regulatory element binding protein (CREB) in both basal and hormone-mediated expression of the phosphoenolpyruvate carboxykinase (PEPCK) gene.
    Xing L; Quinn PG
    Mol Endocrinol; 1993 Nov; 7(11):1484-94. PubMed ID: 8114762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repression of the human glycoprotein hormone alpha-subunit gene by glucocorticoids: evidence for receptor interactions with limiting transcriptional activators.
    Chatterjee VK; Madison LD; Mayo S; Jameson JL
    Mol Endocrinol; 1991 Jan; 5(1):100-10. PubMed ID: 1708098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that glucocorticoid- and cyclic AMP-induced apoptotic pathways in lymphocytes share distal events.
    Dowd DR; Miesfeld RL
    Mol Cell Biol; 1992 Aug; 12(8):3600-8. PubMed ID: 1378529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A.
    Nordeen SK; Bona BJ; Moyer ML
    Mol Endocrinol; 1993 Jun; 7(6):731-42. PubMed ID: 8395651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of dexamethasone and beta-adrenergic receptor agonists on the nerve growth factor gene transcription.
    Colangelo AM; Mallei A; Johnson PF; Mocchetti I
    Brain Res Mol Brain Res; 2004 May; 124(2):97-104. PubMed ID: 15135217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid receptor-independent transcriptional induction of cytochrome P450 3A1 by metyrapone and its potentiation by glucocorticoid.
    Wright MC; Wang XJ; Pimenta M; Ribeiro V; Paine AJ; Lechner MC
    Mol Pharmacol; 1996 Oct; 50(4):856-63. PubMed ID: 8863830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of 3 beta-hydroxysteroid dehydrogenase and 17 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels by cyclic adenosine 3',5'-monophosphate and phorbol myristate acetate in human choriocarcinoma cells.
    Tremblay Y; Beaudoin C
    Mol Endocrinol; 1993 Mar; 7(3):355-64. PubMed ID: 8387158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types.
    Webster JC; Huber RM; Hanson RL; Collier PM; Haws TF; Mills JK; Burn TC; Allegretto EA
    Endocrinology; 2002 Oct; 143(10):3866-74. PubMed ID: 12239098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid interference between glucocorticoids and cAMP-activated signalling in hypothalamic neurones prevents binding of phosphorylated cAMP response element binding protein and glucocorticoid receptor at the CRE-Like and composite GRE sites of thyrotrophin-releasing hormone gene promoter.
    Díaz-Gallardo MY; Cote-Vélez A; Charli JL; Joseph-Bravo P
    J Neuroendocrinol; 2010 Apr; 22(4):282-93. PubMed ID: 20136691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors.
    Beck CA; Estes PA; Bona BJ; Muro-Cacho CA; Nordeen SK; Edwards DP
    Endocrinology; 1993 Aug; 133(2):728-40. PubMed ID: 8344212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering.
    Ratman D; Vanden Berghe W; Dejager L; Libert C; Tavernier J; Beck IM; De Bosscher K
    Mol Cell Endocrinol; 2013 Nov; 380(1-2):41-54. PubMed ID: 23267834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proenkephalin gene expression in C6 rat glioma cells: potentiation of cyclic adenosine 3',5'-monophosphate-dependent transcription by glucocorticoids.
    Joshi J; Sabol SL
    Mol Endocrinol; 1991 Aug; 5(8):1069-80. PubMed ID: 1658636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoid antagonist RU 486 reverses agonist-induced apoptosis and c-myc repression in human leukemic CEM-C7 cells.
    Thompson EB; Thulasi R; Saeed MF; Johnson BH
    Ann N Y Acad Sci; 1995 Jun; 761():261-75. PubMed ID: 7625725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoids regulate the expression of the mouse urocortin II gene: a putative connection between the corticotropin-releasing factor receptor pathways.
    Chen A; Vaughan J; Vale WW
    Mol Endocrinol; 2003 Aug; 17(8):1622-39. PubMed ID: 12764078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Killing of immature CD4+ CD8+ thymocytes in vivo by anti-CD3 or 5'-(N-ethyl)-carboxamide adenosine is blocked by glucocorticoid receptor antagonist RU-486.
    Jondal M; Okret S; McConkey D
    Eur J Immunol; 1993 Jun; 23(6):1246-50. PubMed ID: 8099013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.